Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

Target Validation Information
TTD IDTTDS00407
Target NameProto-oncogene tyrosine-protein kinase LCK    
Type of TargetSuccessful target    
Drug Potency against TargetVX-680Ki = 520 nM[1]
AZD-0530IC50 < 4 nM[2]
PD-0166326;PD-166326IC50 < 5 nM[3]
PD-0173952IC50 < 5 nM[3]
PD-0173955;PD-17395IC50 < 5 nM[3]
PD-0173958IC50 < 5 nM[3]
PD-0180970IC50 < 5 nM[3]
PD-0179483IC50 < 5 nM[3]
PD-0173956IC50 < 5 nM[3]
(4-Phenoxy-phenyl)-quinazolin-4-yl-amineIC50 < 8 nM[4]
JNJ-10198409IC50 = 100 nM[5]
4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazolineIC50 = 1000 nM[6]
Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2IC50 = 11000 nM[7]
Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2IC50 = 11000 nM[7]
A-770041IC50 = 147 nM[8]
SU 6656IC50 = 150 nM[9]
A-641359IC50 = 20 nM[8]
CGP-57380IC50 = 2500 nM[9]
2-(3,4,5-Trihydroxy-benzylidene)-malononitrileIC50 = 3000 nM[10]
AG-1879IC50 = 31 nM[9]
BMS-536924IC50 = 341 nM[11]
A-420983IC50 = 37 nM[12]
NM-PP1IC50 = 460 nM[9]
RPR-108518AIC50 = 500 nM[6]
ZM-336372IC50 = 570 nM[9]
CEP-5104IC50 = 6400 nM[13]
LAVENDUSTIN AIC50 = 8000 nM[14]
3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamideIC50 = 89 nM[15]
6-o-tolylquinazolin-2-amineIC50 = 94 nM[16]
AZD-1152-HQPA;BarasertibKi = 170 nM[17]
TG-100435Ki = 29.4 nM[18]
Ref 1Nat Med. 2004 Mar;10(3):262-7. Epub 2004 Feb 22.VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. To Reference
Ref 2J Med Chem. 2006 Nov 2;49(22):6465-88.N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. To Reference
Ref 3Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. To Reference
Ref 4Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. To Reference
Ref 5J Med Chem. 2005 Dec 29;48(26):8163-73.(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. To Reference
Ref 6Bioorg. Med. Chem. Lett. 7(4):417-420 (1997) To Reference
Ref 7J Med Chem. 1998 Jun 18;41(13):2252-60.Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. To Reference
Ref 8Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22. Epub 2005 Oct 10.Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. To Reference
Ref 9Biochem J. 2007 Dec 15;408(3):297-315.The selectivity of protein kinase inhibitors: a further update. To Reference
Ref 10J Med Chem. 1993 Nov 12;36(23):3556-64.Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. To Reference
Ref 11J Med Chem. 2005 Sep 8;48(18):5639-43.Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. To Reference
Ref 12Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6.A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. To Reference
Ref 13J Med Chem. 2008 Sep 25;51(18):5680-9. Epub 2008 Aug 21.Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models. To Reference
Ref 14J Med Chem. 1993 Oct 1;36(20):3010-4.Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. To Reference
Ref 15Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8. Epub 2007 Apr 13.N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. To Reference
Ref 16J Med Chem. 2006 Sep 21;49(19):5671-86.Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. To Reference
Ref 17J Med Chem. 2007 May 3;50(9):2213-24. Epub 2007 Mar 21.Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. To Reference
Ref 18Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. Epub 2006 Nov 7.Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543